BACKGROUND: The role of natural aeroallergen exposure in modulating allergen-specific immune responses is not well understood. OBJECTIVE: We sought to examine relationships between mouse allergen exposure and mouse-specific immune responses. METHODS: New employees (n = 179) at a mouse facility underwent repeated assessment of mouse allergen exposure, skin prick tests (SPTs), and measurement of mouse-specific IgG levels. Relationships between the mean level of exposure, variability of exposure (calculated as log deviation), and time to development of immunologic outcomes were examined by using Cox proportional hazards models. RESULTS: By 24 months, 32 (23%) participants had experienced a positive SPT response, and 10 (8%) had mouse-specific IgG₄. The incidence of a positive SPT response increased as levels of exposure increased from low to moderate, peaking at 1.2 ng/m³, and decreased beyond this point (P = .04). The more variable the exposure was across visits, the lower the incidence of a positive SPT response (hazard ratio [HR], 0.17; 95% CI, 0.07-0.41). Variability of exposure was an independent predictor of a positive SPT response in a model that included both exposure metrics. In contrast, the incidence of mouse-specific IgG₄ increased with increasing levels of mouse allergen exposure (HR, 2.9; 95% CI, 1.4-6.0), and there was evidence of a higher risk of mouse-specific IgG₄ with greater variability of exposure (HR, 6.3; 95% CI, 0.4-95.2). CONCLUSION: Both the level and variability of mouse allergen exposure influence the humoral immune response, with specific patterns of exposure associated with specific immunophenotypes. Exposure variability might be a more important predictor of a positive SPT response, whereas the average exposure level might be a more important predictor of mouse-specific IgG₄.
BACKGROUND: The role of natural aeroallergen exposure in modulating allergen-specific immune responses is not well understood. OBJECTIVE: We sought to examine relationships between mouse allergen exposure and mouse-specific immune responses. METHODS: New employees (n = 179) at a mouse facility underwent repeated assessment of mouse allergen exposure, skin prick tests (SPTs), and measurement of mouse-specific IgG levels. Relationships between the mean level of exposure, variability of exposure (calculated as log deviation), and time to development of immunologic outcomes were examined by using Cox proportional hazards models. RESULTS: By 24 months, 32 (23%) participants had experienced a positive SPT response, and 10 (8%) had mouse-specific IgG₄. The incidence of a positive SPT response increased as levels of exposure increased from low to moderate, peaking at 1.2 ng/m³, and decreased beyond this point (P = .04). The more variable the exposure was across visits, the lower the incidence of a positive SPT response (hazard ratio [HR], 0.17; 95% CI, 0.07-0.41). Variability of exposure was an independent predictor of a positive SPT response in a model that included both exposure metrics. In contrast, the incidence of mouse-specific IgG₄ increased with increasing levels of mouse allergen exposure (HR, 2.9; 95% CI, 1.4-6.0), and there was evidence of a higher risk of mouse-specific IgG₄ with greater variability of exposure (HR, 6.3; 95% CI, 0.4-95.2). CONCLUSION: Both the level and variability of mouse allergen exposure influence the humoral immune response, with specific patterns of exposure associated with specific immunophenotypes. Exposure variability might be a more important predictor of a positive SPT response, whereas the average exposure level might be a more important predictor of mouse-specific IgG₄.
Authors: Elizabeth C Matsui; Robert A Wood; Cynthia Rand; Sukon Kanchanaraksa; Lee Swartz; Peyton A Eggleston Journal: J Allergy Clin Immunol Date: 2004-05 Impact factor: 10.793
Authors: M J Nieuwenhuijsen; V Putcha; S Gordon; D Heederik; K M Venables; P Cullinan; A J Newman-Taylor Journal: Occup Environ Med Date: 2003-02 Impact factor: 4.402
Authors: C Almqvist; A-C Egmar; G Hedlin; M Lundqvist; S L Nordvall; G Pershagen; M Svartengren; M van Hage-Hamsten; M Wickman Journal: Clin Exp Allergy Date: 2003-09 Impact factor: 5.018
Authors: Corinne A Keet; Wayne G Shreffler; Roger D Peng; William Matsui; Elizabeth C Matsui Journal: J Allergy Clin Immunol Date: 2013-11-28 Impact factor: 10.793
Authors: Wanda Phipatanakul; Elizabeth Matsui; Jay Portnoy; P Brock Williams; Charles Barnes; Kevin Kennedy; David Bernstein; Joann Blessing-Moore; Linda Cox; David Khan; David Lang; Richard Nicklas; John Oppenheimer; Christopher Randolph; Diane Schuller; Sheldon Spector; Stephen A Tilles; Dana Wallace; James Sublett; Jonathan Bernstein; Carl Grimes; J David Miller; James Seltzer Journal: Ann Allergy Asthma Immunol Date: 2012-12 Impact factor: 6.347
Authors: Susan Feistenauer; Ingrid Sander; Jörg Schmidt; Eva Zahradnik; Monika Raulf; Markus Brielmeier Journal: J Am Assoc Lab Anim Sci Date: 2014-07 Impact factor: 1.232
Authors: Ashley N Newton; Meghan Davis; Kirsten Koehler; Wayne Shreffler; Sharon Ahluwalia; Nervana Metwali; Peter S Thorne; Beverly J Paigen; Elizabeth C Matsui Journal: Ann Work Expo Health Date: 2017-10-01 Impact factor: 2.179
Authors: Torie Grant; Jennifer Dantzer; Corinne Keet; Roger Peng; Beverly J Paigen; Mary Krevans; Karol Hagberg; Jean Curtin-Brosnan; Wayne Shreffler; Elizabeth C Matsui Journal: Allergy Asthma Proc Date: 2018-07-01 Impact factor: 2.873